Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis

Jihye Park¹, Kyu Sik Jung¹, Hye Won Lee¹,², Beom Kyung Kim¹,²,³, Seung Up Kim¹,²,³, Do Young Kim¹,²,³, Sang Hoon Ahn¹,²,³, Kwang Hyub Han¹,²,³, and Jun Yong Park¹,²,³

¹Department of Internal Medicine, Yonsei University College of Medicine, ²Yonsei Liver Center, Yonsei University Health System, and ³Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

INTRODUCTION

Renal failure is a challenging complication of cirrhosis. Patients with cirrhosis and renal failure are at high risk for death while awaiting transplantation and have an increased frequency of complications. The model for end-stage liver disease score derived from measurements of serum bilirubin, the international normalized ratio of prothrombin time, and serum creatinine (SCR) was introduced as an aid to organ allocation among candidates for liver transplantation. Maintaining renal function is critical for ensuring a positive prognosis in cirrhosis patients.

Chronic hepatitis B (CHB) viral infections are known to have adverse effects on kidney function. Rarely, CHB viral infections can cause deposition of immune complexes, leading to secondary glomerulopathies. Also, various factors such as old age, diabetes mellitus (DM), metabolic syndrome, high blood pressure, human immunodeficiency virus (HIV) or hepatitis C virus coinfection, nephrotoxic drugs, end-stage liver disease, and solid organ transplantation are related to a decrease in kidney function. In addition to infection with hepatitis B virus (HBV), there are many factors associated with decreased renal function in CHB patients. In order to improve treatment of these patients, we must better understand these contributing factors.

Treatments for HBV infection include nucleoside analogues such as lamivudine, telbivudine, and entecavir (ETV), or nucleotide analogues including adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF). TDF and ETV have been recommended as first line nucleos(t)ide analogues (NUCs) for their antiviral effects, reduced drug resistance, and fewer side effects.

NUCs are excreted through the kidney and are known to contribute to a risk of renal impairment attributable to alterations in renal tubular transporters, apoptosis, and mitochondrial toxicity. NUC-associated nephrotoxicity is dose-dependent;
therefore, the dose of antiviral agents is adjusted when used in patients with impaired renal function (creatinine clearance <50 mL/min).9 Renal tubular dysfunction develops in 15% of patients treated with ADV or TDF for 2 to 9 years and is partially reversible when the antiviral agent is changed.9 Currently, there are no definite conclusions regarding nephrotoxicity associated with long-term use of ETV and TDF. ETV and TDF treatments are well tolerated in patients with decompensated liver disease.11 However, there are case reports of TDF-associated Fanconi syndrome and nephrotic syndrome.12 Consequently, there is some controversy surrounding the renal effects of NUCs in patients with CHB, especially compensated and decompensated HBV-related cirrhosis. Clinical trials have reported a relatively good renal safety profile for these drugs; however, there are a few reports of tubular damage leading to renal insufficiency after the use of TDF.13–15

In this study, we aimed to analyze changes in renal function in patients with compensated and decompensated cirrhosis treated with ETV or TDF for 96 weeks, and to compare the effects of ETV and TDF on renal function in HBV-related cirrhosis patients.

MATERIALS AND METHODS

1. Patients and study design

We performed a retrospective cohort study of 235 consecutive treatment-naive patients with HBV-related cirrhosis who were treated with ETV or TDF between December 2012 and November 2013 at Severance Hospital, Seoul, Korea (162 CHB patients who were treated with ETV monotherapy and 73 CHB patients who were treated with TDF monotherapy). Initially, we identified 353 patients who had been administered ETV (72.8%) or TDF (27.2%) for HBV-related cirrhosis: age ≥18 years, hepatitis B surface antigen carrier for ≥6 months; pathologic or clinical evidence of cirrhosis, including nodularity/splenomegaly on liver imaging and/or thrombocytopenia; presentation with the first episode of liver decompensation defined as the occurrence of complications, such as ascites, variceal bleeding, encephalopathy, or spontaneous bacterial peritonitis.16 Study exclusion criteria included patients with a history of hepatocellular carcinoma within 24 months of treatment, patients that died within 24 months of treatment, patients treated for less than 24 months, patients with massive bleeding events, and patients with baseline estimated glomerular filtration rates (eGFR) below 60 mL/min (Fig. 1). These criteria were considered to be confounding factors that would interfere with an objective analysis of any associations observed between the treatment and renal function.

The general treatment of patients followed the guidelines of the Korean Association for the Study of the Liver.17 Patients were identified using the Severance Hospital Liver Disease Cohort Registry (SOLID CORE), which is an internal web-based electronic medical record that encompasses CHB patients treated with antiviral therapy at Severance Hospital, Yonsei University College of Medicine. The study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Severance Hospital.

For each patient, medical records were reviewed to obtain demographic information, baseline CHB characteristics, and comorbidities including hypertension, DM, history of hepatocellular carcinoma, history of organ transplantation, use of diuretics, use of nonsteroidal anti-inflammatory drugs (NSAID) and pre-existing renal insufficiency. Other risk factors for renal disease, including massive bleeding events and concomitant medications were also recorded.

Fig. 1. Recruitment algorithm. A total of 353 consecutive patients treated with entecavir or tenofovir for hepatitis B-related cirrhosis were included. Among them, patients with a history of hepatocellular carcinoma (HCC) within 24 months of treatment, patients who died within 24 months of treatment, patients treated for less than 24 months, patients with massive bleeding events, and patients with baseline estimated glomerular filtration rates (eGFR) of less than 60 mL/min were excluded based on our exclusion criteria. A total of 235 patients were selected for the final statistical analysis.
2. Renal classifications

Renal function was monitored every 3 to 6 months for every patient. Renal insufficiency was defined as an eGFR of less than 60 mL/min as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\textsuperscript{18} Nephrotoxicity associated with TDF and ETV treatments was assessed by measures of renal function such as increased SCr and changes in eGFR. Specific changes in SCr were assessed by review of the medical records after initiation of TDF or ETV therapy; the data were used in the CKD-EPI equation for calculating renal function to determine eGFR. All available SCr assessments from the medical records were used in the data analysis.

3. Statistical analysis

Means and standard deviations were calculated for all continuous variables. Categorical variables were expressed as proportions (%) and analyses were used to compare groups of these variables. Independent sample t-tests were performed to compare means between groups for continuous variables. Multivariate logistic regression analyses were carried out on the combined treatment groups to identify the evaluate predictors for variables including age, sex, DM, hypertension, use of diuretics, use of NSAID, pre-existing renal insufficiency, compensated or decompensated cirrhosis, and antiviral agents. All statistical analyses were assessed using the SPSS version 20.0 (IBM Corp., Armonk, NY, USA). A p-value less than 0.05 was considered statistically significant.

RESULTS

1. Characteristics of the patients and data collection

Data were collected from January 1, 2012 to August 1, 2015. Baseline characteristics are summarized in Table 1. Prior to treatment initiation, mean age was 55.8±8.5 years, and 66.0% of the study participants were male. All patients were Asian. Similar percentages of both treatment groups had DM (ETV 21.6% and TDF 19.2%) and hypertension (ETV 24.7% and TDF 20.5%). Baseline HBV DNA levels were slightly higher in the ETV treatment group than the TDF treatment group (log 5.6 IU/mL and log 5.4 IU/mL, p=0.125). Baseline creatinine levels (ETV 0.9 mg/dL and TDF 0.8 mg/dL, p=0.209) and eGFR (CKD-EPI equation, ETV 92.7 mL/min/1.73 m\(^2\) and TDF 98.2 mL/min/1.73 m\(^2\), p=0.272) were similar in both treatment groups. There were no significant differences in baseline alanine aminotransferase, aspartate aminotransferase, calcium, phosphate, and blood urea nitrogen levels, use of diuretics, and use of NSAID.

Table 1. Baseline Characteristics

| Variable | Total (n=235) | ETV group (n=162) | TDF group (n=73) | p-value* |
|----------|--------------|------------------|-----------------|----------|
| Demographic data | | | | |
| Age, yr | 55.8±8.5 | 55.6±8.4 | 56.4±8.5 | 0.946 |
| Male sex | 155 (66.0) | 110 (68.0) | 45 (61.6) | 0.088 |
| Diabetes mellitus | 49 (20.9) | 35 (21.6) | 14 (19.2) | 0.498 |
| Hypertension | 55 (23.4) | 40 (24.7) | 15 (20.5) | 0.220 |
| Decompensated LC/compensated LC | 52 (22.1)/183 (77.9) | 32 (19.8)/130 (80.2) | 20 (27.3)/53 (72.7) | 0.014 |
| NSAID medication | 27 (11.5) | 18 (11.1) | 9 (12.3) | 0.738 |
| Diuretics medication | 17 (7.2) | 13 (8.0) | 4 (5.5) | 0.515 |
| Laboratory data | | | | |
| HBV DNA log_{10} IU/mL | 5.4±1.5 | 5.6±1.6 | 5.4±1.3 | 0.125 |
| HBeAg positive/negative | 101 (42.3)/138 (57.7) | 73 (44.0)/93 (56.0) | 28 (38.3)/45 (61.7) | 0.091 |
| AST, IU/L | 107.8±362.2 | 114.7±420.0 | 92.5±177.6 | 0.699 |
| ALT, IU/L | 106.1±271.9 | 109.3±300.9 | 99.0±194.1 | 0.800 |
| Calcium, mg/dL | 8.7±0.5 | 8.7±0.5 | 8.7±0.5 | 0.180 |
| Phosphate, mg/dL | 3.5±2.1 | 3.6±2.5 | 3.3±0.5 | 0.292 |
| Blood urea nitrogen, mg/dL | 13.6±4.1 | 13.6±4.1 | 13.6±4.3 | 0.829 |
| Creatinine, mg/dL | 0.8±0.2 | 0.9±0.2 | 0.8±0.2 | 0.209 |
| eGFR (CKD-EPI), mL/min/1.73 m$^2$ | 94.4±12.673 | 92.7±12.8 | 98.2±11.68 | 0.272 |

Data are presented as mean±SD or number (%).

ETV, entecavir; TDF, tenofovir; LC, liver cirrhosis; NSAID, nonsteroidal anti-inflammatory drug; HBV, hepatitis B virus; HBeAg, hepatitis B envelope antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.

*p-values for comparing the ETV and TDF groups.
2. Changes in renal markers

We analyzed renal function change over time in ETV-treated and TDF-treated patients. However, there were no significant changes in eGFR from baseline in either the ETV- or TDF-treated groups at weeks 96 (CKD-EPI, ETV –1.68% and TDF –5.03%, p=0.358) (Table 2); changes in SCr from baseline in both ETV- and TDF-treated groups were also statistically insignificant (ETV 2.54% and TDF 9.09%, p=0.396). Also, subanalysis of patients with compensated cirrhosis and decompensated cirrhosis were demonstrated in renal function change. The mean eGFR was 0.72% lower in the ETV-treated group with compensated cirrhosis at week 96 than at baseline, and the mean eGFR was 5.37% lower in the TDF-treated group after treatment than at baseline (p=0.220). The mean eGFR was 5.57% lower in the ETV-treated group with decompensated cirrhosis after treatment than at

| Table 2. Changes in Renal Markers |
|----------------------------------|
| **Marker** | **Group (n)** | **Baseline** | **Week 48** | **Week 96** | **LS mean±SE change (%) from baseline to week 96** | **p-value** |
| eGFR (CKD-EPI), mL/min/1.73 m² | | | | | | |
| All patients | ETV group (162) | 92.73±12.77 | 89.50±15.79 | 90.69±16.53 | –1.68 | 0.358 |
| | TDF group (73) | 98.18±11.68 | 95.77±11.75 | 91.11±13.71 | –5.03 | 0.220 |
| Compensated cirrhosis patients | ETV group (130) | 92.03±13.06 | 89.16±14.75 | 90.77±15.50 | –0.72 | 0.978 |
| | TDF group (53) | 97.96±11.78 | 94.42±11.39 | 92.64±13.62 | –5.37 | 0.081 |
| Decompensated cirrhosis patients | ETV group (32) | 95.56±11.29 | 90.88±19.69 | 90.34±19.50 | –5.57 | 0.778 |
| | TDF group (20) | 98.75±11.70 | 99.35±12.22 | 94.35±14.21 | –4.13 | 0.095 |
| Creatinine, mg/dL | | | | | | |
| All patients | ETV group (162) | 0.87±0.16 | 0.90±0.26 | 0.91±0.22 | 2.54 | 0.396 |
| | TDF group (73) | 0.76±0.17 | 0.79±0.16 | 0.82±0.16 | 9.09 | 0.285 |
| Compensated cirrhosis patients | ETV group (130) | 0.89±0.16 | 0.91±0.20 | 0.89±0.20 | 1.27 | 0.911 |
| | TDF group (53) | 0.76±0.17 | 0.80±0.15 | 0.82±0.18 | 9.11 | 0.881 |
| Decompensated cirrhosis patients | ETV group (32) | 0.81±0.13 | 0.87±0.30 | 0.98±0.09 | 7.72 | 0.056 |
| | TDF group (20) | 0.78±0.19 | 0.78±0.18 | 0.83±0.04 | 9.05 | 0.021 |
| Calcium, mg/dL | | | | | | |
| All patients | ETV group (162) | 8.66±0.55 | 8.84±0.53 | 8.94±0.61 | 3.46 | 0.218 |
| | TDF group (73) | 8.74±0.55 | 8.81±0.54 | 8.89±0.46 | 2.06 | 0.548 |
| Phosphate, mg/dL | | | | | | |
| All patients | ETV group (162) | 3.63±2.46 | 3.83±4.66 | 3.39±0.56 | 1.69 | 0.548 |
| | TDF group (73) | 3.34±0.58 | 3.36±0.56 | 3.34±0.53 | 3.20 | 0.548 |

LS, least square; SE, standard error; eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; ETV, entecavir; TDF, tenofovir. *p-values for comparing the ETV and TDF groups.

| Table 3. Changes in Renal Markers Following Treatment |
|----------------------------------|
| **Marker** | **ETV** | **TDF** | **p-value** |
| SCR increase >0.2 mg/dL | 6 (8.2) | 16 (9.9) | 0.686 |
| eGFR<60 mL/min (CKD-EPI) | 2 (2.7) | 6 (3.7) | 0.524 |
| Decrease in eGFR >20% (CKD-EPI) | 5 (6.8) | 13 (8.0) | 0.754 |
| Decompensated cirrhosis patients (n=52) | | | |
| SCR increase >0.2 mg/dL | 2 (10.0) | 6 (18.8) | 0.463 |
| eGFR<60 mL/min (CKD-EPI) | 0 | 2 (6.3) | 0.374 |
| Decrease in eGFR >20% (CKD-EPI) | 2 (10.0) | 5 (15.6) | 0.563 |

TDF, tenofovir; ETV, entecavir; SCR, serum creatinine; eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration. *p-values for comparing the ETV and TDF groups.
baseline, and the mean eGFR was 4.13% lower in the TDF-treated group after treatment than at baseline (p=0.778); however, these results were statistically insignificant.

During treatment, increases in SCr >0.2 mg/dL over baseline values occurred in 9.9% of ETV-treated patients and 8.2% of TDF-treated patients (p=0.686) (Table 3); we found no significant differences in renal function between the treatment groups using this direct measure of nephrotoxicity. Using the CKD-EPI equation, we calculated a >20% decrease in eGFR from baseline in 13 (8.0%) and five (6.8%) patients in the ETV-treatment and TDF-treatment groups, respectively (p=0.754). Six (3.7%) patients in the ETV-treatment group and two (2.7%) patients in the TDF-treatment group developed an eGFR below 60 mL/min/1.73 m² during therapy (p=0.524), which differed from their baseline values.

### 3. Changes in eGFR in patients with renal insufficiency

A sub-analysis of patients with baseline CKD stage 2 (60 to 89 mL/min/1.73 m²) showed that three (4.1%) patients in the TDF-treated group had improvements in eGFR (≥90 mL/min/1.73 m²) after 96 weeks of treatment (Table 4). In comparison, 21 (13.0%) patients in the ETV-treated group had improvements in eGFR (≥90 mL/min/1.73 m²) after 96 weeks of treatment. A subanalysis of patients with baseline CKD stage showed that 16 (21.9%) of the TDF-treated group had impaired renal function after treatment than at baseline, whereas 31 (19.1%) of the ETV-treated group had impaired renal function after treatment than at baseline.

### Table 4. Changes in eGFR Category (CKD-EPI Equation)

| Patients in eGFR categories at end of study | <60 | 60–90 | >90 | Total |
|--------------------------------------------|-----|-------|-----|-------|
| **Tenofovir group**                        |     |       |     |       |
| Patients in eGFR categories at baseline    |     |       |     |       |
| 60–90                                      | 2 (2.7) | 11 (15.1) | 3 (4.1) | 16 (21.9) |
| >90                                        | 0 | 14 (19.2) | 43 (58.9) | 57 (78.1) |
| Total                                      | 2 (2.7) | 25 (34.2) | 46 (63.0) | 73 (100) |
| Impaired renal function                    | 16 (21.9) |       |     |       |
| **Entecavir group**                        |     |       |     |       |
| Patients in eGFR categories at baseline    |     |       |     |       |
| 60–90                                      | 4 (2.5) | 37 (22.8) | 21 (13.0) | 62 (38.3) |
| >90                                        | 2 (1.2) | 25 (15.4) | 73 (45.1) | 100 (61.7) |
| Total                                      | 6 (3.7) | 62 (38.3) | 94 (58.0) | 162 (100) |
| Impaired renal function                    | 31 (19.1) |       |     |       |

Data are presented as number (%).

eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.

### Table 5. Independent Risk Factor for Decreases in eGFR >20% (CKD-EPI Equation)

| Variable                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | p-value               | HR (95% CI)         | p-value               |
| Tenofovir (vs entecavir)        | 1.195 (0.410–3.485) | 0.745                 | 1.393 (0.434–4.472) | 0.578                 |
| Male sex                        | 1.355 (0.465–3.946) | 0.578                 |                       |                       |
| Age                             | 0.977 (0.924–1.034) | 0.426                 |                       |                       |
| History of hypertension         | 2.957 (1.104–7.918) | 0.003                 | 2.378 (0.769–7.356)  | 0.133                 |
| History of diabetes mellitus    | 5.855 (2.168–15.813) | 0.001                | 5.692 (1.823–17.776) | 0.003                |
| Use of diuretics                | 8.104 (2.612–25.147) | 0.001                | 20.170 (5.043–80.672) | <0.001               |
| Use of NSAID                    | 2.985 (0.990–9.002) | 0.052                 |                       |                       |
| eGFR (CKD-EPI)                  | 1.060 (1.014–1.108) | 0.009                 | 1.043 (1.002–1.084) | 0.038                |
| Compensated cirrhosis (vs decompensated cirrhosis) | 2.418 (0.887–6.592) | 0.084                 |                       |                       |

eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; HR, hazard ratio; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.
4. Independent risk factors for a decline in eGFR >20% (CKD-EPI equation)

Univariate analysis and multivariate analysis of factors associated with markers of renal impairment were carried out on the combined treatment groups for all patients (n=235). By multivariate analysis, significant factors associated with a decrease in eGFR >20% included baseline eGFR (adjusted odds ratio [OR], 1.043; 95% confidence interval [CI], 1.002 to 1.084; p=0.038), DM (OR, 5.692; 95% CI, 1.823 to 17.776; p=0.003), and use of diuretics (OR, 20.170; 95% CI, 5.043 to 80.671; p<0.001) (Table 5).

**DISCUSSION**

About one-third of the population worldwide has been infected with HBV at some point, and 350 to 400 million people are chronic HBV surface antigen carriers. In many of these patients, HBV infection proceeds to cirrhosis and eventually end-stage liver disease, hepatocellular carcinoma, and death. Antiviral therapy in HBV-related compensated and decompensated cirrhosis patients helps regress fibrosis and reverse cirrhosis. In these patients, ETV and TDF are preferred for their potency and minimal resistance.

ETV and TDF are preferred in CHB patients for their less adverse effects compared to other antiviral agents. There are few reports of TDF-associated nephrotoxicity in HIV-positive and CHB patients. However, real life observations studies of CHB patients state that using TDF does not significantly reduce renal function compared to ETV. The studies analyzed eGFR decrease magnitude and concluded cumulative incidences of patients with decreased eGFR >20% did not differ between ETV and TDF cohorts. However, there are limited data in cirrhosis patients, who have potential renal dysfunction.

This study evaluated renal function changes in HBV-related compensated and decompensated cirrhosis patients who received ETV or TDF treatment for 2 years. To our knowledge, this is the first study to examine renal impairment of ETV and TDF in cirrhosis patients. The mean eGFR was 5.02% lower in the decompensated group at week 96 than at baseline, and the mean eGFR was 2.07% lower in the compensated group after treatment than at baseline (p=0.397). These data suggest that ETV and TDF have similar renal safety profiles.

The Cockcroft-Gault equation, modification of diet in renal disease (MDRD) equation, and CKD-EPI equation are commonly used to calculate eGFR. Recent studies have shown that the CKD-EPI equation is more accurate than the MDRD equation for estimating eGFR. Thus, in this study we calculated eGFR using the CKD-EPI equation to evaluate renal function in ETV- and TDF-treated patients. In patients with an increase in SCR of 0.2 mg/dL or greater, we additionally analyzed the proportion of patients with CKD stage grade 3 or higher and impaired eGFR (CKD-EPI) >20% of baseline for each group. There were no statistically significant differences observed.

Since many patients included in this study had multiple medical histories and comorbidities, we proceeded with multivariate analysis to determine variables related to impaired renal function. DM, low baseline eGFR, and the use of diuretics were determined to be independent risk factors for impaired renal function, consistent with previous studies. Although DM is a risk factor for impaired renal function in ETV- and TDF-treated patients, it is difficult to delineate whether the renal impairment is attributable to treatment with antiviral agents or DM-associated nephropathy. Extreme caution is required when using ETV and TDF in patients with comorbidities. In addition to DM, low baseline eGFR as an independent risk factor, reflects the importance of dose adjustment when administering ETV and TDF.

Multivariate analysis revealed that use of ETV or TDF is not an independent risk factor for impaired renal function (OR, 1.393; 95% CI, 0.434 to 4.472; p=0.578).

The data used for these analyses were gathered from several physicians instead of one, which is a limitation of this study. Also, the study design, based on short-term retrospective chart reviews, is a limitation. Short duration of TDF use in our patients is our limitation, and long term study is required in the future.

In conclusion, in patients with HBV-related compensated or decompensated cirrhosis, there was no significant difference concerning impaired renal function between ETV and TDF for 2 years. With treatment-related renal safety concern, regular renal function should be monitored, especially high-risk patients such as those with baseline low eGFR, DM, and receiving concomitant nephrotoxic drugs.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGEMENTS**

This study was supported by a fund of the HBV cohort study (4800-4845-300-260, 2016-ERS103-00) from the Korea Centers for Disease Control and Prevention.

**REFERENCES**

1. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290.
2. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233-243.
3. Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971;2:234-237.
4. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
5. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
6. Ahn SH, Heo J, Park JY, et al. A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. J Gastroenterol Hepatol 2016;31:865-871.
7. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S185-S195.
8. Quesada PR, Esteban LL, García JR, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm 2015;37:865-872.
9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
10. Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1317-1325.
11. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
12. Hwang HS, Park CW, Song MJ. Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B mono-infection. Hepatology 2015;62:1318-1320.
13. Lee S, Park JY, Song K, et al. Comparison of the effects of telbivudine and entecavir on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver 2015;9:776-783.
14. Barrios A, García-Benayas T, González-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18:960-963.
15. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004;24:415-418.
16. Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015;61:1809-1820.
17. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75.
18. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307:1941-1951.
19. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893.
20. Ahn SS, Chon YE, Kim BK, et al. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. Clin Mol Hepatol 2014;20:261-266.
21. Najjar Z, Gupta L, Pritchard-Jones J, et al. A survey of Sydney general practitioners’ management of patients with chronic hepatitis B. Med J Aust 2016;204:74.
22. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
23. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
24. Yip B, Chaung K, Wong CR, et al. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci 2012;57:3011-3016.
25. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:941-946.
26. Ha NB, Ku K, Ha NB, Chaung KT, Trinh HN, Nguyen MH. Renal function in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or entecavir monotherapy: a matched case-cohort study. J Clin Gastroenterol 2015;49:873-877.
27. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.